GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us

Article Type

Article

Changed

Fri, 02/01/2019 - 10:36

Display Headline

GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us

Author(s)

Derek P. Chew, MBBS

David J. Moliterno, MD

Article PDF

content_68_1017.pdf

Author and Disclosure Information

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Issue

Cleveland Clinic Journal of Medicine - 68(12)

Publications

Cleveland Clinic Journal of Medicine

Topics

Cardiology

Drug Therapy

Vascular

Page Number

1017-1023

Sections

Interpreting Key Trials

Author(s)

Derek P. Chew, MBBS

David J. Moliterno, MD

Author(s)

Derek P. Chew, MBBS

David J. Moliterno, MD

Author and Disclosure Information

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Author and Disclosure Information

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Article PDF

content_68_1017.pdf

Article PDF

content_68_1017.pdf

Issue

Cleveland Clinic Journal of Medicine - 68(12)

Issue

Cleveland Clinic Journal of Medicine - 68(12)

Page Number

1017-1023

Page Number